Studies Enrolling Volunteers


This chart below is a summary of all actively enrolling studies.

Research StudyEligibilityContact Person
Emory Alzheimer's Disease Research Center Honor Research Registry
Longitudinal study of changes in memory and other cognitive skills
  • Aging people with no memory problems
  • People of any age with MCI, Alzheimer's disease or other forms of dementia
  • Willing to participate in additional research studies
  • Study partner available to participate in visits
Samantha Heldenberg
shelden@emory.edu
404-712-7542
ADNI-3
Alzheimer's Disease Neuroimaging Initiative
  • Age 55-90
  • Healthy controls/Diagnosis of MCI/AD
  • Study partner available for all visits
Adrianne Crank
adrianne.nicole.crank@emory.edu
404-778-0664

BAN2401-301: Clarity
A 18-month infusion study to confirm safety and efficacyof BAN2401 in Subjects with Early Alzheimer's Disease

Learn more about BAN2401-301: Clarity
  • Diagnosis of MCI due to AD or mild AD
  • 50-90 yrs old
  • Study partner available for all visits
  • Willing to undergo MRI & PET scans
Kay Colon-Motas
kay.maria.colon-motas@emory.edu
404-727-7349
EMERALD
Montelukast Therapy for Alzheimer's disease
  • Early (prodromal to mild) AD
  • 50 years of age or older
  • Please contact study coordinator for other criteria
Shakyra Tyus
shakyra.d.tyus@emory.edu
404-712-6332

Emory Healthy Aging Study
Longitudinal study of aging

Learn more about the Healthy Aging Study
  • 18 years of age or older
  • Read and speak English fluently
Luke Maschinot
luke.j.maschinot@emory.edu
404-727-1338

HEART
8-month study of an FDA-approved blood pressure medicine in the African-American population.

Learn more about the HEART study
  • African-American
  • 45 years and older
  • Have or did have a parent with dementia
Danielle Verble
danielle.d.verble@emory.edu
404-712-7085
AHEAD 3-45
A 4-year infusion study to reduce amyloid accumulation as measured by PET imaging
  • Cognitively normal
  • 55 - 80 years old
Phyllis Vaughn
pvaughn@emory.edu
404-712-6901

Alector
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
  • Persons with a progranulin gene mutation and at risk of developing FTD symptoms as evidenced by a biomarker
  • Persons with a progranulin gene mutation and diagnosed with FTD
  • 18 - 85 years old
Kayla Irons
kairons@emory.edu
404-712-4463

Detailed Descriptions of Research Studies and Clinical Trials

James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center

Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center

The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking. By joining Honor you will learn about new research studies that are seeking volunteers. You will also receive our newsletter and invitations to educational events.

All Honor volunteers must have a “study partner” accompany them to their research visit. Your study partner will be asked questions about your memory and thinking. They will also be asked about your day to day functioning. A study partner is someone who has at least 10 hours of contact with you each week.

For more information about this research study, please call Samantha Heldenberg at 404-712-7542 or email shelden@emory.edu.

Allan Levey, MD, PhD
Director, Emory Alzheimer's Disease Research Center
Emory University Department of Neurology

Long-term study (2-4 years) being conducted as part of the Alzheimer’s Disease Neuroimaging Initiative to characterize changes in the brain associated with MCI and AD. Subjects will under multiple MRI and PET scans, lumbar puncture, blood draws and cognitive testing.

For more information about this research study, please call Becky Byram at 404-712-0195 or email rbyram@emory.edu.

Allan Levey, MD, PhD

This multinational study is using a placebo or the study drug, to determine safety and efficacy and to explore the dose response of this drug. In this 18-month study, a drug/placebo is infused biweekly (once every 2 weeks). Subjects will be from 2 clinical subgroups: MCI due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Effectiveness of drug treatment will be assessed using cognitive tests, as well as biological markers (MRI, PET, CSF, blood).

For more information about this research study, please call Michelle Wiles at 404-778-0664 or emailmkwiles@emory.edu.

Link to study website »

Ihab Hajjar, MD

This is a one-year, double-blind placebo-controlled randomized clinical trial that compares montelukast to placebo in individuals with mild cognitive impairment (MCI) and early Alzheimer's disease (AD) dementia. The measures include cognitive function, CSF biomarkers and neuroimaging (cerebral perfusion and markers of vascular brain damage).

Participants will be treated with montelukast (escalating doses:10, 20 to 40 mg) or matched placebo.

For more information about this research study, please call Shakyra Tyus at 404-712-6332 or email shakyra.d.tyus@emory.edu.

Ihab Hajjar, MD

The study will consist of a screening period of up to 12 weeks in length following the signing of informed consent. Eligible patients will then undergo baseline visit assessments (Day 1) prior to receiving the first dose of blinded study drug (gantenerumab or placebo). Patients will continue in the double-blind treatment period for 104 weeks.

For more information about this research study, please call Aaron Milloy at 404-712-6855 or email aaron.m.milloy@emory.edu.

For more information about this research study, please call William Hu at 404-727-4174 or email wthu@emory.edu.

James Lah, MD, PhD

This study is the largest clinical research study every conducted it Atlanta. It is designed to further our scientific understanding of how we age so we can better understand, prevent and treat diseases of aging. To participate, simply sign up online at www.healthyaging.emory.edu, complete a brief health history questionnaire and occasionally respond to various surveys and complete online memory tasks.

For more information about this research study, please call Luke Maschinot at 404-727-1338 or email luke.j.maschinot@emory.edu.

Link to study website »

Caregiving for a loved one with Alzheimer’s or another form of neurodegenerative disease is usually a new role. Some people gradually take on the role of caregiver as their spouse or parent has increasing memory or thinking problems. Others are thrust into the role. Perhaps your mother died who was caring of your father. Suddenly you become your father’s caregiver, a role for which you had no preparation.

When you have a family member with Alzheimer’s or another neurodegenerative disease there are new skills to learn and new resources that will be needed. It will be important to “plan for the future”.